×
S&P 500   3,818.86 (-0.07%)
DOW   31,034.88 (+0.28%)
QQQ   283.80 (+0.09%)
AAPL   139.28 (+1.34%)
MSFT   260.09 (+1.41%)
META   163.48 (+1.74%)
GOOGL   2,229.43 (-0.48%)
AMZN   109.27 (+1.74%)
TSLA   683.13 (-2.13%)
NVDA   155.06 (-2.98%)
NIO   21.83 (-2.37%)
BABA   115.99 (-0.66%)
AMD   77.93 (-3.53%)
MU   55.91 (-3.37%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.68 (-3.34%)
F   11.52 (-2.46%)
DIS   95.62 (-0.31%)
AMC   13.73 (+2.62%)
PFE   50.91 (+0.49%)
PYPL   71.36 (-0.64%)
NFLX   177.89 (-0.95%)
S&P 500   3,818.86 (-0.07%)
DOW   31,034.88 (+0.28%)
QQQ   283.80 (+0.09%)
AAPL   139.28 (+1.34%)
MSFT   260.09 (+1.41%)
META   163.48 (+1.74%)
GOOGL   2,229.43 (-0.48%)
AMZN   109.27 (+1.74%)
TSLA   683.13 (-2.13%)
NVDA   155.06 (-2.98%)
NIO   21.83 (-2.37%)
BABA   115.99 (-0.66%)
AMD   77.93 (-3.53%)
MU   55.91 (-3.37%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.68 (-3.34%)
F   11.52 (-2.46%)
DIS   95.62 (-0.31%)
AMC   13.73 (+2.62%)
PFE   50.91 (+0.49%)
PYPL   71.36 (-0.64%)
NFLX   177.89 (-0.95%)
S&P 500   3,818.86 (-0.07%)
DOW   31,034.88 (+0.28%)
QQQ   283.80 (+0.09%)
AAPL   139.28 (+1.34%)
MSFT   260.09 (+1.41%)
META   163.48 (+1.74%)
GOOGL   2,229.43 (-0.48%)
AMZN   109.27 (+1.74%)
TSLA   683.13 (-2.13%)
NVDA   155.06 (-2.98%)
NIO   21.83 (-2.37%)
BABA   115.99 (-0.66%)
AMD   77.93 (-3.53%)
MU   55.91 (-3.37%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.68 (-3.34%)
F   11.52 (-2.46%)
DIS   95.62 (-0.31%)
AMC   13.73 (+2.62%)
PFE   50.91 (+0.49%)
PYPL   71.36 (-0.64%)
NFLX   177.89 (-0.95%)
S&P 500   3,818.86 (-0.07%)
DOW   31,034.88 (+0.28%)
QQQ   283.80 (+0.09%)
AAPL   139.28 (+1.34%)
MSFT   260.09 (+1.41%)
META   163.48 (+1.74%)
GOOGL   2,229.43 (-0.48%)
AMZN   109.27 (+1.74%)
TSLA   683.13 (-2.13%)
NVDA   155.06 (-2.98%)
NIO   21.83 (-2.37%)
BABA   115.99 (-0.66%)
AMD   77.93 (-3.53%)
MU   55.91 (-3.37%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.68 (-3.34%)
F   11.52 (-2.46%)
DIS   95.62 (-0.31%)
AMC   13.73 (+2.62%)
PFE   50.91 (+0.49%)
PYPL   71.36 (-0.64%)
NFLX   177.89 (-0.95%)
NASDAQ:OPGN

OpGen Stock Forecast, Price & News

$0.54
+0.01 (+2.47%)
(As of 06/29/2022 03:29 PM ET)
Add
Compare
Today's Range
$0.53
$0.55
50-Day Range
$0.32
$0.69
52-Week Range
$0.31
$3.72
Volume
1,925 shs
Average Volume
393,619 shs
Market Capitalization
$25.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13
30 days | 90 days | 365 days | Advanced Chart

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock Forecast (MarketRank)

Overall MarketRank

1.80 out of 5 stars

Medical Sector

803rd out of 1,433 stocks

Medical Laboratories Industry

19th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
OpGen logo

About OpGen (NASDAQ:OPGN)

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OPGN Stock News Headlines

OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com
OpGen (NASDAQ:OPGN) Stock Rating Reaffirmed by HC Wainwright
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPGN
Employees
91
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/29/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$2.13
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+291.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-34.81 million
Net Margins
-680.36%
Pretax Margin
-676.84%

Debt

Sales & Book Value

Annual Sales
$4.31 million
Book Value
$1.06 per share

Miscellaneous

Free Float
45,971,000
Market Cap
$25.29 million
Optionable
Not Optionable
Beta
-0.53














OpGen Frequently Asked Questions

Should I buy or sell OpGen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen
or view top-rated stocks.

What is OpGen's stock price forecast for 2022?

3 brokers have issued 12-month target prices for OpGen's stock. Their OPGN stock forecasts range from $1.25 to $3.00. On average, they predict OpGen's stock price to reach $2.13 in the next twelve months. This suggests a possible upside of 291.3% from the stock's current price.
View analysts' price targets for OpGen
or view top-rated stocks among Wall Street analysts.

How has OpGen's stock price performed in 2022?

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 45.7% and is now trading at $0.5431.
View the best growth stocks for 2022 here
.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for OpGen
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Thursday, May, 12th. The medical research company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The medical research company earned $0.47 million during the quarter, compared to the consensus estimate of $1.05 million. OpGen had a negative trailing twelve-month return on equity of 72.67% and a negative net margin of 680.36%.
View OpGen's earnings history
.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

Who are OpGen's key executives?

OpGen's management team includes the following people:
  • Dr. Oliver Schacht Ph.D., CEO, Pres & Director (Age 51, Pay $600.2k)
  • Mr. Johannes Bacher, Chief Operating Officer (Age 53, Pay $396.52k)
  • Mr. Albert Weber, CFO & Corp. Sec. (Age 59)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 51)
  • Mr. Michael Farmer, VP of Marketing
  • Ms. Faranak Atrzadeh, Chief Marketing & Scientific Affairs Officer
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 63)
  • Mr. Derek Joesting, Sr. VP of US Sales
  • Dr. Arne Materna, MD & CEO of Ares Genetics GmbH

What other stocks do shareholders of OpGen own?

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.88%), Renaissance Technologies LLC (2.43%), GSA Capital Partners LLP (0.21%) and Arete Wealth Advisors LLC (0.18%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends for OpGen
.

Which major investors are selling OpGen stock?

OPGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for OpGen
or view top insider-selling stocks.

Which major investors are buying OpGen stock?

OPGN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Arete Wealth Advisors LLC. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht.
View insider buying and selling activity for OpGen
or or view top insider-buying stocks.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $0.54.

How much money does OpGen make?

OpGen (NASDAQ:OPGN) has a market capitalization of $25.29 million and generates $4.31 million in revenue each year. The medical research company earns $-34.81 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 91 workers across the globe.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for OpGen is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at [email protected], or via fax at 301-869-9684.

This page (NASDAQ:OPGN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.